Method Article

Modeling Mitochondrial Disease Using Brain Organoids: A Focus on Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes

DOI:

10.3791/69303

October 10th, 2025

In This Article

Summary

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Brain organoids serve as a valuable model for Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) studies, offering insights into their underlying pathophysiology and providing a platform for drug screening. Organoids derived from cell lines with varying levels of heteroplasmy of disease-causing genes exhibit significant phenotypic differences.

Abstract

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) are mitochondrial disorders most commonly caused by a m.3243A>G variant in mitochondrial tRNALeu. To investigate the pathophysiology of MELAS, we generated brain organoids from multiple induced pluripotent stem cell (iPSC) lines derived from a patient with MELAS carrying the m.3243A>G variant. These lines share an identical nuclear genetic background but differ in their heteroplasmy levels involving the m.3243A>G variant. We observed significant differences in organoid size, morphology, and neural induction efficiency, which correlated with the degree of heteroplasmy. Dissociated neurons from the organoids were transferred into a 2D-culture system, which is convenient and suitable for high-throughput drug screening. The organoids also exhibited significant differences in the formation of neural networks, depending on heteroplasmy levels. Our results suggest that patient-derived iPSC-based organoid models represent a useful platform for studying MELAS mechanisms and for drug screening. This video presents comprehensive and user-friendly methods, including protocols for generating organoids and evaluating phenotypes.

Introduction

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) are mitochondrial diseases that are characterized by neurological dysfunction, stroke-like episodes, and various systemic symptoms. The most common cause is a m.3243A>G variant in the mitochondrial leucine tRNA gene, MT-TL11. This variant is believed to impair taurine modification at the anticodon, thereby reducing leucine translation efficiency and contributing to mitochondrial dysfunction in MELAS2,3,4. Notably, improvements in symptoms have been reported following high-dose taurine administration5,6. However, the presence of non-responders suggests that additional, as yet unidentified, pathophysiological mechanisms may contribute to disease in individuals harboring the m.3243A>G variant.

To elucidate disease mechanisms caused by genetic variants, it is ideal to use experimental models in which all variables are identical except for the causative variant, enabling accurate phenotypic comparisons. Genome-edited cell lines and animal models with corrected variants are often used as controls for nuclear gene disorders. However, repair of mtDNA variants remains technically challenging, even with advanced genome editing technologies7. Therefore, the establishment of experimental models with identical nuclear backgrounds remains challenging. To address this issue, we utilized two induced pluripotent stem cell (iPSC) lines derived from the same patient with MELAS that differ only in their heteroplasmy levels (i.e., the proportion of mitochondrial DNA carrying the MT-TL1 m.3243A>G variant8), and generated brain organoids as a disease model. Although heteroplasmy levels can fluctuate during cell passaging or differentiation, potentially influencing phenotypes and causing batch-to-batch variability in experimental outcomes, patient-derived cells carrying mitochondrial gene variants remain valuable for investigating disease pathogenesis.

In this study, we generated brain organoids from iPSCs derived from a patient with MELAS and investigated their pathophysiology to better understand disease mechanisms. Using two iPSC lines with high and low heteroplasmy levels, we observed significant differences in neural induction efficiency, which correlated with the degree of heteroplasmy. Our findings suggest that patient-derived iPSC-based brain organoids provide a valuable platform for elucidating the mechanisms underlying MELAS and for facilitating drug screening.

Access restricted. Please log in or start a trial to view this content.

Protocol

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

The two iPSC lines (2-6 and 2-8) were derived from the same MELAS patient's fibroblasts using well-established methods8. They differ only in their heteroplasmy levels. The 414C2 iPSC line established from a healthy individual was used as a control. The protocol used in this study followed the guidelines of the Ethics Committee of Kitasato University School of Medicine (#G22-02).

1. Cell culture

  1. Thawing frozen cell stocks
    1. Prepare 6-well plates by coating with laminin according to the manufacturer's instructions.
    2. Warm the culture medium for feeder-free iPSCs containing 10 µM ROCK inhibitor to 37 °C.
    3. Retrieve the frozen iPSC vial from the liquid nitrogen (LqN2) tank and rapidly thaw in a 37 °C water bath.
    4. Transfer the thawed suspension into 10 mL of prewarmed medium. Centrifuge at 120 × g for 5 min at room temperature (22 °C).
    5. Carefully remove the supernatant and gently resuspend the pellet by tapping the tube. Add fresh medium and seed cells into 6-well plates precoated with laminin. Incubate at 37 °C in a humidified incubator with 5% CO2.
  2. Medium change
    1. Replace the medium (without ROCK inhibitor) every 1-2 days.

2. Generation of cerebral organoids

  1. Initiation of differentiation (Day 0)
    1. Remove medium from iPSC (~70-80% confluent) culture plates. Wash cells with PBS.
    2. Add enzyme solution and incubate at 37 °C for 5 min.
    3. Add medium to stop the reaction. Transfer cells into a 15 mL tube. Centrifuge at 190 × g for 5 min at room temperature (22 °C).
    4. Resuspend the pellet in 1 mL of differentiation medium containing 30 µM ROCK inhibitor, 5 µM SB431542, and 2.5 µM IWP-2.
      NOTE: The basic medium is the same as that used in step 1.1.2.
    5. Count the cells. Seed 3 × 103 cells in 100 µL per well in U-shaped, 96-well, low-attachment plates. Incubate for 6 days at 37 °C, 5% CO2.
  2. Medium change (Day 6)
    1. Transfer organoids (from step 2.1.5) from a 96-well plate to a 10 cm dish using a wide-bore pipette. Add 50 µL of medium (DMEM/F12 with 1% N2, 1% glutamine substitute 1% NEAA, 2.5 µM IWP-2, 5 µg/mL heparan sulfate, and 1% PS) to each well of a new 96-well plate.
      NOTE: Use wide-bore pipettes throughout the experiments when transferring organoids to avoid disrupting their 3D-structure. Additionally, 8-channel pipettes are helpful for performing experiments quickly and accurately.
    2. Collect organoids into 2 mL tubes. Carefully remove the medium so as not to aspirate the organoids and add 1.5 mL of DMEM/F12. Repeat 3x to wash the organoids.
    3. Remove medium and add 500 µL of fresh medium to tubes with organoids. Transfer all organoids to a 10 cm dish, then add 5 mL of medium to make it easier to pick up each organoid.
    4. Pick up a single organoid using a micropipette adjusted to 50 µL and transfer it to one well of 96-well plate. Repeat until all of the organoids are transferred to the 96-well plate (final volume 100 µL). Incubate for 3 days at 37 °C, 5% CO2.
  3. Medium change (Day 9)
    1. (Optional) Transfer organoids to a 10 cm dish when using 8-channel pipettes. Skip step 2.3.1 when using single-channel micropipettes and proceed to step 2.3.2.
    2. Collect organoids into 2 mL tubes. Wash 3x with DMEM/F12 as step 2.2.2.
    3. Resuspend in differentiation medium (1:1 DMEM/F12 and neurobasal) containing 1% N2, 2% B27 without vitamin A, 100 µM 2-mercaptoethanol (ME), 2.5 µg/mL insulin, 1% glutamine substitute, 0.5% NEAA, and 1% basement membrane extract.
      NOTE: Prepare small aliquots of basement membrane extract for single use and store at -20 °C until needed. Thaw the extract at 4 °C without allowing it to exceed 8 °C, then mix it into cold medium and warm the medium at room temperature for approximately 30 min.
    4. Transfer ~10 organoids per well into a 6-well plate. Adjust final volume of medium for 1 well to 2 mL. Culture statically for 6 days at 37 °C, 5% CO2.
  4. Medium change (Day 15)
    1. Collect organoids into 15 mL tubes. Leave the tube undisturbed until all organoids have settled. Remove supernatant and add fresh differentiation medium (same as step 2.3.3 but with B27 + vitamin A).
      NOTE: Usually, organoids settle at the bottom of the tube without centrifugation. However, small organoids derived from patient iPSCs may not sink efficiently. In that case, centrifuge the tubes at 120 × g for 3 min at room temperature to collect the organoids.
    2. Transfer ~10 organoids per well into a 6-well plate. Culture statically for 15 days at 37 °C, 5% CO2.
    3. Replace medium every 5-7 days until Day 30.

3. Dissociation of cerebral organoids for 2D culture (Day 30)

  1. Coating plates with poly-L-ornithine (PO)
    1. Prepare PO stock solution by dissolving 10 mg of PO in 66.7 mL of H2O and make small aliquots for single use. Store them at -20 °C until use.
    2. Dilute the PO stock solution 1:5 with H2O and coat culture plates with the diluted solution. Incubate overnight at 37 °C.
  2. Laminin coating
    1. Remove PO and wash wells 3 x 5 min with PBS.
    2. Add laminin (1:1,000 in PBS) and incubate at 37 °C for 3 h or overnight.
      NOTE: Stock solution of laminin is 1 mg/mL. Prepare small aliquots and store at -80 °C until needed.
  3. Dissociation into single neurons
    1. Thaw the dissociation solution at 4 °C for 1 h before use.
    2. Transfer organoids into a 15 mL tube and leave the tube undisturbed until all organoids have settled. Remove supernatant and add 5mL of PBS to rinse organoids.
    3. After removing PBS, add 1 mL of enzyme solution and pipette gently 1–2x. Incubate at 37 °C for 5 min; pipette several times. If necessary, incubate for an additional 2–3 min. Pipette again to complete dissociation.
    4. Centrifuge at 200 × g for 5 min. Remove supernatant, add 1 mL of dispersion solution, and pipette.
    5. Layer isolation solution beneath and centrifuge at 200 × g for 5 min.
    6. Add 1 mL of neuronal medium (neurobasal with 1% B27, 0.25% glutamine substitute, 1% PS) and mix. Pass suspension through a 70 µm strainer into a 50 mL tube.
    7. Count the cells. Seed cells at 1 × 105 cells/cm2 on PO/laminin-coated plates. Replace medium every 4-7 days until Day 60.

4. Harvesting cells and organoids for cellular and molecular analysis

  1. Organoid fixation for immunofluorescence (Day 30)
    1. Harvest organoids (step 2.4.3) into microtubes.
    2. Remove medium carefully not to aspirate organoids, and add 1 mL of PBS to rinse organoids.
    3. Remove PBS carefully not to aspirate organoids, and add 4% paraformaldehyde (PFA) to fix for 30 min at room temperature.
    4. Wash 3x with PBS.
    5. Store at 4 °C until use.
  2. Organoid collection for RT-qPCR (Day 30)
    1. Transfer organoids (step 2.4.3) into microtubes. Wash with PBS as described in step 4.1.2.
    2. Add lysis buffer and snap-freeze in liquid nitrogen (LqN2). Store at −80 °C until use.
  3. Cell fixation for immunofluorescence (Day 60)
    1. Remove culture medium and add PBS to wash cells.
    2. Fix in 4% PFA for 15 min at room temperature.
    3. Remove PFA and add PBS to wash cells. Repeat this step 3x.
    4. Store at 4 °C until use.

5. RT-qPCR

  1. Extract total RNA from organoids according to the kit manufacturer's instructions.
  2. Synthesize cDNA from 1 µg of total RNA prepared in Step 5.1 according to the kit manufacturer's instructions in a total reaction volume of 20 µL.
  3. Perform quantitative PCR using the following primers: FOXG1_forward: CGCCAGATTTCCATGTGTGC; FOXG1_reverse: GTTCTCAAGGTCTGCGTCCA; ACTB_forward: TGAAGTGTGACGTGGACATC; ACTB_reverse: GGAGGAGCAATGATCTTGAT. Set up the final concentration for each reaction as follows: 1x fluorescent master mix, 0.25 µM forward primer, 0.25 µM reverse primer. Total reaction volume is 15 µL, including 0.2 µL of cDNA from Step 5.2. Use the following PCR conditions: initial denaturation at 95 °C for 1 min; 40 cycles of 95 °C for 15 s and 60 °C for 30 s.
  4. Normalize FOXG1 expression to ACTB as the internal control.

6. Immunofluorescence staining

  1. Incubate organoids (Day 30) in 10% sucrose for 1 h at 4 °C, then 30% sucrose for ≥3 h at 4 °C.
  2. Mount organoids in embedding medium and prepare cryosection (10 µm) using cryostat. Store sections on slide glasses at −20 °C until use.
  3. Remove embedding medium by PBS wash (2 x 5 min).
  4. Permeabilize in 0.3% PBST for 10 min. Wash with PBS.
  5. Block in 10% normal goat serum in 0.1% PBST for 1 h. Incubate overnight at 4 °C with primary antibodies: anti-FOXG1 (1:200), anti-TUBB3 (1:500-1:1,000). Wash 3x with PBS.
  6. Incubate with secondary antibody (1:500) + Hoechst 33258 (1:500) for 1 h. Wash 3x with PBS.
  7. Mount and observe under a confocal microscope.

7. Heteroplasmy analysis

  1. Harvest iPSCs using cell scrapers and transfer to microtubes. Add 0.5 mL of PBS and centrifuge at 100 × g for 5 min. Remove supernatant and proceed to Step 7.2.
  2. Extract total DNA according to the kit manufacturer's instructions.
  3. Set up the final concentration for each PCR reaction: 1x fluorescent master mix, 0.25 µM forward primer, 0.25 µM reverse primer. Total reaction volume is 15 µL, including 50 ng of total DNA from Step 7.2. Use the following PCR conditions: initial denaturation at 95 °C for 1 min; 40 cycles of 95 °C for 15 s and 60 °C for 30 s. Primer sequences are as follows: MELASwt_foward: gtttgttaagatggcagagc; MELASwt_reverse: ggaattgaacctctgactgtaaagttt; MELASmut_foward: gtttgttaagatggcagg; MELASmut_reverse: ggaattgaacctctgactgtaaagttt; FBXO15_ foward: gccaggaggtcttcgctgta; FBXO15_ reverse: aatgcacggctagggtcaaa.
  4. Use threshold cycle values to calculate mitochondrial DNA copy number (mutant vs wild-type).
  5. Normalize to FBXO15 nuclear gene copy number.

8. Evaluation of organoid size and shape

  1. Capture images of organoids using microscope with TIFF format.
  2. Measure size and circularity using open-source image analysis software. Open the TIFF files saved in Step 8.1 by clicking File | Open and selecting the file. Choose Freehand selections and trace the organoid. Then Click Analyze | Measure. The values for Area and Circularity in the results were used for the analysis in Step 8.3.
  3. Analyze the data by performing a t-test to evaluate whether there are significant differences compared with the control lines using statistical software.

Access restricted. Please log in or start a trial to view this content.

Results

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

We generated brain organoids and conducted 2D neuronal cultures using a relatively simple protocol with minor modifications based on Nakamura et al.9 (Figure 1). In the previous protocol, V-shaped 96-well plates were used, whereas in this study, we used U-shaped 96-well low-attachment plates to allow the cells to naturally aggregate at the center of each well. Using the healthy control iPSC line 414C2, we successfully induced brain organoids containing FOXG1-positive ...

Access restricted. Please log in or start a trial to view this content.

Discussion

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Organoids induced from human embryonic stem cells (ESCs)/iPSCs represent promising disease models for rare intractable diseases, whereas the generation of brain organoids typically requires extended culture periods lasting several months10 and the use of expensive equipment, such as an engineered container that continuously stirs the culture medium and maintains stable conditions for long-term 3D cell culture. In this study, we established brain organoids within a short timeframe using standard ce...

Access restricted. Please log in or start a trial to view this content.

Disclosures

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

The authors have no conflicts of interest to disclose.

Acknowledgements

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

The 414C2 iPSCs were obtained from RIKEN BRC. Funding support was provided by JSPS KAKENHI (24H00648 to M.F., 23K08971 to C.S.) and AMED Translational Research Network Program (25yf0126001j002 to M.F.). This work was supported by a fellowship of the German Academic Exchange Service (DAAD) to F.B.

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
10 cm cell culture dishcorning353003
6 well plate ultra low attachment surfacecorning3471
70 μm cell strainercorning352350
Accutasenacalai tesque12679-54enzymes used to dissociate iPSCs
B27 supplementThermofischer scientific17504001
B27 supplement minus vitamin AThermofischer scientific12587010
β-mercaptoethanol (2-ME)sigmaM3148Discard according to the institution's rules.
Cell Culture 6 well multi platecorning353046
cell saver tipBMBio ECOBMT-200Wwide-bore pipett tip
cell scrapersSUMITOMO BAKELITECO., LTD.MS-93100
Confocal microscopeZeissLSM710
CryostatLeicaCM3050
Culture Mouse Laminin 1R&D3400-010-02used for coating plates for 2D cultures of dissociated neurons
DMEM/F12FUJIFILM Wako Pure Chermical Co.042-30795
Fluorescence Mounting MediumDAKOS302380-2mounting medium
FOXG1 antibodyabcamab196868
GlutamaxThermofischer scientific35050061
Goat anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor Plus 488Thermofischer scientificA32723
Goat anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor Plus 555Thermofischer scientificA32732
Heparan Sulfate (HS)sigmaH7640
High capacity RNA-to-cDNA KitThermofischer scientific4387406used to synthesize cDNA from RNA
Hoechst 33258Thermofischer scientificH3569
ImageJversion 1.52aused to measure size and circularity of organoids
iMatrix-511 silkTakara Bio Inc.892021coating for plates for iPSC culture
insulinFUJIFILM Wako Pure Chermical Co. 090-06481
IWP2Tocris Bioscience3533
Keyence BZ-X810KeyenceBZ-X810used to capture images for Figure 3A
LSM710Carl Zeiss AGconfocal microscope
LSM980Carl Zeiss AGconfocal microscope
LUNA Universal qPCR Master MixNew England BiolabsM3003
MatrigelCorning354277
N2 supplementThermofischer scientific17502001
Neurobasal mediumThermofischer scientific21103049
Neuron Dissociation Solution FUJIFILM Wako Pure Chermical Co.291-78001
non-essential amino acids (NEAA)nacalai tesque06344-56
Normal Goat SerumJackson ImmunoResearch Inc. 005000121
Nunclon Sphera 96-Well, Nunclon Sphera-Treated, U-Shaped-Bottom MicroplateThermofischer scientific174929
paraformaldehyde (PFA)nacalai tesque09154-85Discard according to the institution's rules.
PBSnacalai tesque14249-24
PBSnacalai tesque27575-31
penicillin/streptomycin (PS)nacalai tesque26253-84
Poly-L-ornithine (PO)sigmaP3655
Polyoxyethylene(10) Octylphenyl Ether (Triton)FUJIFILM Wako Pure Chermical Co.168-11805
PRISM GraphPadversion 9.5.0
QIAamp DNA Mini Kit QIAGEN51304used to extract total DNA
RNeasy Mini KitQIAGEN74104used to extract total RNA
SB-431542Cayman Chemical13031
slide glassesMATSUNAMICRE-05
StemFit AK02NTakara Bio Inc.AK02Nmedium used for the culture of undiffereintiated iPSCs and from differentiation Day 0 to Day 6
SucroseFUJIFILM Wako Pure Chermical Co.196-00015
Tissue-Tek O.C.T. CompoundSakura Finetek Japan Co.,Ltd.4583Cryopreservation medium
TUBB3 antibodyPromegaG712A
Y27632FUJIFILM Wako Pure Chermical Co.030-24021ROCK inhibitor
ZENCarl Zeiss AG2.3SP1(black edition)software to analyze the images taken  with confocal microscope (LSM710)
ZENCarl Zeiss AG2.6 (blue edition)software to analyze the images taken  with confocal microscope (LSM980)

References

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,
  1. Sproule, D. M., Kaufmann, P. Mitochondrial encephalopathy, lactic acidosis, and strokelike episodes: basic concepts, clinical phenotype, and therapeutic management of MELAS syndrome. Ann N Y Acad Sci. 1142, 133-158 (2008).
  2. Kirino, Y., Suzuki, T. Human mitochondrial diseases associated with tRNA wobble modification deficiency. RNA Biol. 2 (2), 41-44 (2005).
  3. Shaffer, S. W., et al. Role of taurine in the pathologies of MELAS and MERRF. Amino Acids. 46, 47-56 (2014).
  4. Shaffer, S. W., Kim, H. W. Effects and mechanisms of taurine as a therapeutic agent. Biomol Ther. 26, 225-241 (2018).
  5. Rikimaru, M., et al. Taurine ameliorates impaired mitochondrial function and prevents stroke-like episodes in patients with MELAS. Intern Med. 51 (24), 3351-3357 (2012).
  6. Ohsawa, Y., et al. Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicentre, open-label, 52-week phase III trial. J Neurol Neurosurg Psychiatry. 90 (5), 529-536 (2019).
  7. Tolle, I., Tiranti, V., Prigione, A. Modeling mitochondrial DNA diseases: from base editing to pluripotent stem-cell-derived organoids. EMBO Rep. 24 (4), e55678(2023).
  8. Fujikura, J., et al. Induced pluripotent stem cells generated from diabetic patients with mitochondrial DNA A3243G mutation. Diabetologia. 55 (6), 1689-1698 (2012).
  9. Nakamura, M., et al. Pathological progression induced by the frontotemporal dementia-associated R406W tau mutation in patient-derived iPSCs. Stem Cell Rep. 13 (4), 684-699 (2019).
  10. Pagliaro, A., Artegiani, B., Hendriks, D. Emerging approaches to enhance human brain organoid physiology. Trends Cell Biol. 35 (6), 483-499 (2025).
  11. Kodaira, M., et al. Impaired respiratory function in MELAS-induced pluripotent stem cells with high heteroplasmy levels. FEBS Open Bio. 5, 219-225 (2015).
  12. Homma, K., et al. Taurine rescues mitochondria-related metabolic impairments in the patient-derived induced pluripotent stem cells and epithelial-mesenchymal transition in the retinal pigment epithelium. Redox Biol. 41, 101921(2021).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Tags

MELAS SyndromeInduced Pluripotent Stem CellsOrganoid GenerationNeural Network FormationHeteroplasmy LevelsHigh Throughput ScreeningImmunofluorescence StainingRT qPCR Analysis

Related Articles